GLP1R and myocardial infarction: Furthermore, Sauvé et al. demonstrated that genetic deletion and pharmacological inhibition of DPP IV, which inhibits the production of GLP-1 (9-36), improved cardiovascular outcomes following myocardial infarction in a murine model [33].